Subject Index

A to G mutation of mitochondrial DNA at np 3242, 75
Acetyl-L-carnitine, heart mitochondria and, 260
Acetylcholinesterase (AChE), neural activity and, 352
Acetylcholinesterase-associated protease, APP and, 172
Adenosine diphosphate (ADP) translocase, heart mitochondria and, 257
Adenosine triphosphate (ATP), VSMC and EC treated by, 235
Adenyl cyclase system, dual regulation of, 285
Adrenergic nerve activity, 265
Aged mice, 306
Aged rats, hippocampus of, 307
Aging
  antioxidant enzyme activities during, 395
  cellular immortalization and, 57
  hypothesis (or model or theory) of
    free radical, 362
    mitochondrial, 102
    oxidative stress, 1
    protease inhibitor, 12
  late onset sporadic SDAT and, 155
  life span extension and, 321
  mitochondrial oxidative phosphorylation and, 68-69
  neurochemical studies on, 410
  recombinant growth hormone and, 430
  senescence-accelerated mouse and, 410
  tandem duplications and, 87
Aging-associated deleted mtDNA, proportions of, 25
Albumin, SOD and, 224
Alpha-lipoic acid, free radicals and, 325
Aluminum, APP and, 174
Alzheimer's disease
  amyloid β-protein in, 184
  antioxidant enzyme activities and, 398
  Ca^{2+} homeostasis and, 305
  hypothesis on pathogenesis of, 152
  industrialized nations and, 348
  reactive oxygen species and, 120
  receptor-effector coupling dysfunctions in, 294
Amfoneric acid, methamphetamine and, 209
Amyloid, neuritic plaques and, 154
Amyloid β-protein, fractionation of, 184
Amyloid precursor protein, expression of, in human lymphocytes, 169
Antioxidant
  amyloid toxicity and, 129
  catecholestrogen as, 419
  definition of, 322
Antioxidant defense system, 6
Antioxidant enzyme activities, deprenyl and, 391
Antioxidant supplementation, Alzheimer's disease and, 163
Antisense oligonucleotides, inhibition of APP expression by, 177
Apolipoprotein E, late onset familial and sporadic SDAT and, 157
Apoptosis, DNA fragmentation and, 137
Atherogenesis
  LDL in, 245
  lipid hydroperoxides and, 428
Atherosclerosis, lesions in, 331
ATP synthase, mitochondrial F_0F_1, 57, 62
ATPase module, cellular immortalization and, 57
Autoimmune disease, A to G mutation at np 3243 and, 77

Back-to-back primers, 86
BCE-001, 448
Beta-adrenoceptor stimulation, myocardial contraction and, 284
Beta-amyloid
  Alzheimer's disease and, 297
  amplifying effect of, 315
Beta-amyloid peptide
  Alzheimer's disease and, 121
  plaque and, 153
Beta-amyloid precursor protein (APP), C-terminal fragment of, 414
Beta-amyloid precursor protein (APP)-like immunoreactivity, 415
Beta-carotene, antioxidant capacity of, 331
Brain
  antioxidant enzyme activities in, 397
  cAMP and PI signal transduction pathways in, 280
  circulatory status of, 224
Butylated hydroxytoluene (BHT), free radical reactions and, 326-327

C-terminal fragment of APP, 414
Caenorhabditis elegans, 325
Calbindin, loss of, in hippocampus, 307
Calcium influx, impaired learning and, 354
Calcium permeability transition, mitochondrial, 53
Calretinin, loss of, in hippocampus, 307

Carboxy terminal (CT) peptides, amyloidogenic, 175
Cardiolipin, heart mitochondria and, 260
Cardiomyocytes, ecNOS gene in, 236
Cardiovascular aging, cellular and molecular mechanisms of, 283
Cardiovascular system, nervous control of, 264
Catalase (CAT)
  deprenyl and, 391
  Drosophila and, 326
Cataractogenesis, melatonin and, 370
Catecholestrogen, natural antioxidant properties of, 419
Cell surface receptors, three classes of, 283
Cellular homeostasis disruption, 8
Cellular immortalization, ATPase module and, 57
Cellular senescence, 59
Centenarian, mtDNA mutations in somatic cells and, 109
Centrophenoxine (CPH) (*also called* meclophenoxate), 448
Cholesterol
  aged membranes and, 281
  oxidative stress sensitivity and, 115
Cholesterol distribution, Apo E and, 316
Cholesterol transport, reverse, 246
Cholesterol-loaded liposomes, 49
Choline acetyltransferase (ChAT), aFGF and, 342
Cholinergic hypothesis, geriatric memory impairment and, 351
Cholinesterase (ChE), Alzheimer's disease and, 351
Chromosome 1, 14, and 21, early onset familial SDAT and, 159-160
Clorgyline, methamphetamine and, 209
^{60}Co γ-ray, 2-OHE$_2$ and, 422
^{60}Co irradiation, exposure of mitochondria to, 63
Cytochrome oxidase activity, kinetic studies of, 253

D-Cycloserine, memory enhancement and, 354
Deafness, diabetes mellitus and, 72
Deferoxamine, methamphetamine and, 209
Dementia pugilistica (DP), 161
Depolarization, mouse brain cells and, 2
Deprenyl
  antioxidant enzyme activities by, 391
  methamphetamine and, 209
  protection of nigral neurons by, 379
Desaturase, 46
Diabetes mellitus, mitochondrial gene abnormalities and, 72
Dietary restriction, oxidative stress and, 7
Diffuse Lewy body disease, Alzheimer's disease and, 196
Dissociated brain cells, 206
Dizocilpine, blockade of channel site with, 354
DNA fragmentation, apoptosis and, 137
Dopamine, deprenyl and, in the striatum, 382
Dopamine neurons
  damage of, 212
  protection of, 213
Dopaminergic receptor coupling, signal transduction and, 277
Down's syndrome
  amyloid β-protein in, 184
  chromosome 21 and, 160
Drosophila melanogaster, 325

Early molecular events of human aging, tandem duplications and, 99
Electron paramagnetic resonance (EPR) spectroscopy, 123
Endothelial cells, 2-OHE$_2$ and, 426
Endothelial cells nitric oxide synthase (ecNOS) gene, 236
Endothelium-derived relaxing factor (EDRF), nitric oxide and, 233
Enzymes, phase I and II, 332
Ethoxyquin, 328

Females, longevity of, 328
Fibroblast growth factor receptor, aFGF receptor density and, 343
Fluorescence activated cell sorter, 198
Fluorescence anisotropy, 279
Free cellular calcium, Alzheimer's disease and, 305
Free radical diseases, 328
Free radical production, age increase and, 4
Free radical reactions
  amyloid peptides promoting, 121
  late onset sporadic SDAT and, 155
  three stages of, 321
Free radicals
  ^{60}Co orradiation of mitochondria and, 65
  Parkinson's disease and, 207
  reactive oxygen species and, 24
  vascular endothelial cells and, 224

G protein dysfunction, 296
G proteins, adenylyl cyclase and, 287
$G_0\alpha$ protein, increase of, in aging, 414
Gene abnormalities, mitochondrial, 72
Genomes, mitochondrial, 51
Genomic damage, melatonin and, 368
Gerbils, PBN and, 325
Geriatric prevention, nootropica in, 444

Glial fibrillary acidic protein (GFAP)-like immunoreactivity, 415
Gliosis, senescence-accelerated mouse P8 and, 417
Glutamate uptake, Na^+-dependent, 128
Glutamatergic hypothesis, geriatric memory dysfunction, 352
Glutathione
  intramitochondrial GSH levels and, 64
  oxidized (GSSG), 219
  reduced (GSH), 219
Glutathione peroxidase (GSH Px)
  deprenyl and, 391
  melatonin and, 373
Glycine, NMDA receptor and, 354

Heart, rat, mitochondrial function in, 252
Heparin, SOD and, 224
High-density lipoprotein, coronary heart disease and, 246
Hippocampus, aFGF and, 345
Human mitochondria, lipid peroxide contents of, 35
Human muscle mtDNA, deletions and tandem duplications in, 88
Human skin mtDNA, deletions and tandem duplications in, 90
Human testis mtDNA, deletions and tandem duplications in, 89
Human tissues, large-scale deleted mtDNA in, 33
Hydrogen peroxide, oxidative stress sensitivity and, 114
4-Hydroxy-2-nonenal, 108
8-Hydroxydeoxyguanosine, 103
Hydroxyl radical formation, deprenyl and, 379
Hypertension, essential, 329

Immobilization, recombinant growth hormone and, 431
Immune function, aFGF and, 344
Impaired glucose tolerance (IGT), 73
In vivo gene transfer technique, 233
$Ins(1,4,5)P_3$, PtdIns and, 297
Insulin-dependent diabetes mellitus (IDDM), 73
Intracellular calcium, nitric oxide and, 233

Junction site sequences, tandem duplications of human mtDNA and, 95–96

Kidney, leupeptin and, 12
Kinetic studies, cytochrome oxidase activity, 253

L-Buthionine-[S,R]-sulfoxamine (BSO), GSH depletion and, 221
Lazaroids, free radicals and, 325
Leucopenia, 2-OHE_2 and, 424
Leupeptin, lipofuscin-like substances and, 12
Lewy bodies, Parkinson's disease and, 195
Lewy body disease, glutathione peroxidase and, 219
Lipid peroxidation
  melatonin and, 367
  Parkinson's disease and, 108
Lipid peroxide
  human age and, 36
  ovariectomy and, 421
Lipofuscin-like substances, leupeptin causing accumulation of, 12
Long-term potentiation (LTP), aFGF and, 343
Longevity, mitochondrial genotypes for, 108
Lou Gehrig disease, 329
Low-density lipoprotein, cigarette smoke and, 245
Lymphocytes, human, amyloid precursor protein in, 169
Lysophosphatydlcholine, EDRF effects attenuated by, 239

Macrophages, oxidatively modified LDL and, 245
Manganese superoxide dismutase (Mn-SOD), age-dependent increase of, 38
Maximum life span, compounds reported to increase, 328
Medial septum, aFGF and, 345
MELAS (*see* Mitochondrial myopathy)
Melatonin
  antioxidant action of, 366
  free radicals and, 325
  rhythm of, 363
Membrane, basement, 22
Membrane alterations, signal transduction and 290
Membrane lipid alterations, 45
Memory impairment, neural circuity and, 349
2-Mercaptoethylamine (2-MEA), life span and, 326
Metabolic rate, oxidative stress and, 3
Methamphetamine, dopamine neurons and, 206
Methioninesulfoxide, synthetic amyloid Aβ (1–40) and, 125
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), deprenyl and, 379
1-Methyl-4-phenylpyridinium ion (MPP^+), deprenyl and, 379

Mitochondria
  late onset sporadic SDAT and, 155
  oxygen and, 322
  sonic submitochondrial particles and, 63
Mitochondrial DNA
  deleted
    7,436-bp, 32
    aging-associated, 26
    dietary restriction and, 52
    large scale, 31
    lipid peroxidation and, 39
    somatic accumulation of, 103
  tandem duplications of, 82
Mitochondrial DNA mutations, late onset sporadic SDAT and, 156
Mitochondrial free radical generation, 44
Mitochondrial function, rat heart tissue and, 252
Mitochondrial lipid peroxides, measurement of, 29
Mitochondrial membrane fluidity, 48
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), 104
Molecular pharmacology, cell surface receptors and, 283
Monoamine oxidase B (MAO-B), deprenyl and, 386
Muscarinic receptor
  aFGF and, 341
  signal transmission and, 275
Muscarinic receptor responsiveness, loss of, 112
Muscle atrophy, recombinant growth hormone and, 431
Myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), 72

N-Methyl-D-aspartate (NMDA) receptor, pharmacologic manipulation and, 353
N-tert-Butyl-α-phenylnitrone (PBN), free radical reactions and, 325
Neuritic plaques, neuronal cell loss associated with, 153
Neurofibrillary tangles, SDAT and, 153
Neurospora crassa, 325
Neurotransmitter replacement, Alzheimer's disease, 299
Neutrophils, 311
N^G-Nitro-L-arginine (NARG), 355
Nicotinamide, apoptosis and, 145
Nicotinamide adenine dinucleotide, tBuOOH and, 143
Nicotinamide adenine dinucleotide phosphate (NADPH), tBuOOH and, 143
Nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d), 356
Nigral cell death, glutathione depletion and, 220
Nigral neurons, protection of, by deprenyl, 379
Nimodipine, voltage-dependent calcium channels and, 354
Nitric oxide
  cardiovascular system and, 233
  mitochondrial energy metabolism and, 230
  oxidative stress sensitivity and, 114
Nitric oxide synthase (nNOS), arginine and, 355
Nonadrenergic nerves, neurotransmission and, 264
Noninsulin-dependent diabetes mellitus (NIDDM), 73
Nootropica, geriatric prevention and, 444
Norepinephrine reuptake, adrenergic nerves and, 269

Ovariectomy, 2-OHE_2 and, 420
Oxidative stress
  ^{60}Co irradiation and, 66
  increased sensitivity to, 112
  Parkinson's disease and, 217
  sources of, in aging, 5
  tBuOOH and, 135
Oxygen stress, fragmentation of mtDNA and, 104

Paraquat toxicity, lungs stressed by, 370
Parkinson's disease
  antioxidant enzyme activities and, 398
  free radicals and, 206
  late onset sporadic SDAT and, 161
  lipid peroxidation by-products in, 106–108
  oxidative stress and, 217
Passive avoidance test, aFGF and, 339
Periodic acid Schiff (PAS), 15
Phenserine, therapeutic window of, 352
Phorbor 12,13-dibutylate, binding properties of, 414
Phosphatidylinositol (PI)-hydrolysis, 308
Phospholipase A_2, 47
Phospholipase C system, dual regulation of, 285
Phosphorylation
  cytochrome oxidase activity and, 255
  oxidative, ^{60}Co irradiation and, 67
Phytohemagglutinin (PHA), Ca^{2+} responses and, 311
Pineal gland, 364
Piracetam, 444
PK-11195, neuronal damage and, 413
Plasma levels of norepinephrine, 270

Point mutations in mtDNA, 104
Polyamine, NMDA receptor and, 354
Polyphenols
  free radicals and, 325
  antioxidant capacity of, 331
Polyunsaturated fatty acids, melatonin and, 372
Pramiracetam, 447
Prejunctional α_2-adrenoceptors, 266
Prejunctional β-adrenoceptors, 268
Primer-shift polymerase chain reaction, age-associated mtDNA deletions and, 30
Primers, analysis of duplicated mtDNA and, 85
Protease inhibitor model of aging, 12
Protein, semiconductive model of, 448
Protein kinase C, beta-amyloid production and, 299
Protein oxidation, recombinant growth hormone and, 434
Proximal convoluted tubules, 19

Quinone reductase, antioxidants and, 332

Reactive oxygen species (ROS)
  amyloid peptides and, 124
  damage of mtDNA by, 106
  free radicals and, 24
Receptor recognition site disturbances, Alzheimer's disease and, 295
Recombinant growth hormone, muscle damage and, 430
Reduction potential, 2
Respiration
  cytochrome oxidase activity and, 255
  mitochondrial, 50

Salicylate hydroxyl radical, 208
Senescence-accelerated mouse (SAM)
  aFGF and, 338
  neurochemical studies of, 411
  P1 strain (SAMP1), catecholestrogen and, 419
  P8 strain (SAMP8), aging syndrome of, 412
  R1 control strain (SAMR1), 412
Signal transduction
  disturbances of, in Alzheimer's disease, 295
  neurotransmitter plasticity and, 274
Simian virus 40 (SV40) T protein, 58
Smart drug, nootropica and, 447
Somatic mutations, 83
Spermidine, maze impairment and, 354
Spin labeling, hydrogen peroxide and, 127
Spin trap
  nitroxides and, 323
  detection of free radicals and, 123
Stone 14-unit T-maze, 350
Striatum
  deprenyl and, 382
  Ins(1,4,5)P_3 concentration in, 276
Sucrose density gradient centrifugation, 185
Superoxide dismutase (SOD)
  cigarette smoke and, 248
  deprenyl and, 391
  Drosophila and, 326
  superoxide and nitric oxide radicals and, 224
Synaptosomal membranes, biochemical composition of, 278
Synaptosomes, Ca^{2+} responses and, 308

T lymphocytes, Ca^{2+} homeostasis and, 310
t-Butylhydroperoxide (tBuOOH), oxidative stress and, 135
Tandem duplications of mtDNA
  age-dependent increase in incidence of, 95
  large-scale deletions and, 97
  type II, 84
  type IV, 87
  type IX, 97
Tetraethylammonium (TEA), 311
Thiol proteases, 13
Thrombin, processing of APP by, 171
Transmembrane signaling mechanisms, cardiovascular aging and, 286
Two-dimensional image analysis, intracellular calcium measurement by, 234

Ubiquitin, Lewy bodies and, 203

Vascular endothelial cells, free radicals in, 224
Vascular smooth muscle cells, intracellular calcium in, 233
Vicious cycle, degeneration of cellular components and, 106
Vitamins C and E, antioxidant capacity of, 331

Water maze test, aFGF and, 341

Xenopus oocytes, C-terminal fragment of APP (CT105) amd. 175

Index of Contributors

Adams, J. D., 135-151
Agapito, T. T., 362-378
Aksenov, M., 120-134
Aksenova, M., 120-134
Arai, H., 245-251
Arima, T., 410-418
Asami-Odaka, A., 184-194

Borgeld, H-J. W., 102-111
Butterfield, D. A., 120-134

Carmeli, E., 430-443
Carney, J. M., 120-134
Carrillo, M. C., 391-409
Chang, M. L., 135-151
Chen, J. J., 44-56
Chiueh, C. C., 379-390
Choe, M., 44-56
Choi, W., 169-183
Chong, Y. H., 169-183
Cole, P., 120-134
Coper, H., 274-282
Cowburn, R. F., 294-304

Dencher, N. A., 274-282
Denisova, N., 112-119
Djamgoz, M. B. A., 169-183
Docherty, J. R., 264-273

Eckert, A., 305-320
Erat, S., 112-119

Fares, F. A., 430-443
Förstl, H., 305-320
Fowler, C. J., 294-304
Fraser, S. P., 169-183
Fratello, A., 62-71
Fujimuro, M., 195-205
Fukata, Y., 337-347
Furio, A., 62-71

Garlind, A., 294-304
Gong, J-S., 102-111
Grattagliano, I., 62-71
Greig, N., 348-361
Gruener, N., 430-443
Guerrero, J. M., 362-378
Guerrieri, F., 62-71

Hall, N., 120-134
Hanai, K., 337-347
Harman, D., 152-168, 321-336
Harris, M. E., 120-134
Hartmann, H., 305-320
Hayakawa, M., 102-111
Hengemihle, J., 348-361
Hensley, K., 120-134

Ihara, Y., 184-194, 195-205, 410-418
Ikari, H., 348-361
Ingram, D. K., 348-361
Inoue, K., 224-232
Inoue, M., 224-232
Inukai, M., 233-244
Ivy, G. O., 12-23, 391-409
Iwatsubo, T., 195-205

Jenner, P., 217-223
Jeong, S-J., 169-183
Jimenez, N., 112-119
Joseph, J. A., 112-119

Kanai, S., 12-23, 391-409
Kang, C. M., 44-56
Kao, S-H., 24-43
Katsumata, K., 102-111
Kawaguchi, H., 233-244
Kim, S-H., 169-183
Kimura, H., 337-347
Kita, T., 245-251
Kitamura, Y., 410-418
Kitani, K., xi, 12-23, 391-409
Klaidman, L. K., 135-151
Komura, S., 419-429
Kondo, T., 206-216
Kovalenko, S. A., 102-111
Krause, F., 274-282
Kristal, B. S., 44-56
Krøll, J., 57-61
Kuo, H., 348-361

Lee, H-C., 24-43, 82-101
Lee, V. M-Y., 195-205
Li, A., 337-347

Maeng, Y. S., 44-56
Mark, R., 120-134
Markesbery, W. R., 120-134
Marsden, C. D., 217-223
Mattson, M. P., 120-134
Min, K., 169-183
Miyamoto, A., 283-293
Miyasaka, K., 391-409
Mukherjee, S. K., 135-151
Müller, W. E., 305-320
Muolo, L., 62-71
Murphy, D. L., 379-390

Nagano, Y., 245-251
Nagashima, K., 410-418
Nomura, Y., 337-347, 410-418

O'Neill, C., 294-304
Odawara, M., 72-81
Ohishi, N., 419-429
Ohnuki, T., 410-418
Ohshika, H., 283-293
Ohta, M., 12-23
Oomura, Y., 337-347, 410-418
Owen, A. D., 217-223
Ozawa, T., 102-111

Pablos, M. I., 362-378
Pang, C-Y., 82-101
Papa, S., 62-71
Paradies, G., 252-263
Petrosillo, G., 252-263

Quagliariello, E., 252-263

Reiter, R. J., 362-378
Reznick, A. Z., 430-443
Roopsingh, R., 12-23
Ruggiero, F. M., 252-263

Sasaki, K., 337-347, 410-418
Sasaki, T., 233-244
Sato, Y., 12-23
Schapira, A. H. V., 217-223
Schulze, G., 274-282
Shimada, A., 348-361
Shin, W. S., 233-244
Spangler, E. L., 348-361
Strain, J., 112-119
Subramaniam, R., 120-134
Sugawa, M., 274-282
Suh, Y-H., 169-183
Suzuki, N., 184-194

Tanaka, M., 102-111
Tooyama, I., 337-347
Toyo-oka, T., 233-244
Trojanowski, J. Q., 195-205
Turturro, N., 62-71

Ueda, Y., 245-251
Ueyama, K., 245-251

Velbinger, K., 305-320
Vendemiale, G., 62-71
Villalobos-Molina, R., 112-119

Wang, Y. P., 233-244
Wei, Y-H., 24-43, 82-101
Wu, J. F., 120-134
Wu, R-M., 379-390

Yagi, K., 419-429
Yago, H., 337-347
Yamaguchi, H., 195-205
Yamanaka, Y., 410-418
Yamashina, I., 274-282
Yanagisawa, K., 184-194
Yanaihara, N., 337-347
Yang, R., 1-11
Yang, W. D., 233-244
Yasharel, R., 135-151
Yokode, M., 245-251
Yokosawa, H., 195-205
Yoneda, M., 102-111
Yoshii, H., 337-347
You, B-J., 82-101
Yu, B. P., 1-11, 44-56

Zs.-Nagy, I., 444-452